Cassava Sciences Inc. (SAVA)
NASDAQ (CM) 
Why Cassava Sciences Stock Dived by Almost 11% Today
The biotech is paying $40 million not to acquire a drug or fund a development program, but to satisfy a regulator. The money is going toward a settlement with the Securities and Exchange Commission.
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated clinical trial data related to its Alzheimer's disease drug.
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Alzheimer's drug developer Cassava Sciences Inc SAVA, its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, simufilam.
Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer's clinical trial.
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer's clinical trial
The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Cassava Sciences NASDAQ: SAVA has become a hot topic among traders and active market participants thanks to its recent surge in volatility, liquidity, and overall market performance. Over the past month, shares have climbed 133% and are now more than 190% above their 52-week low.
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
Cassava Sciences, Inc. announced its Q2 earnings earlier today. Management says it hopes to share pivotal Phase 3 study data for Alzheimer's drug candidate simufilam in 2024. The CEO and Head of Research resigned from the company a few weeks ago — possibly related to an ongoing SEC investigation into Cassava.
2 Biotech Stocks Making Moves Today
Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).
Cassava Sciences News: Why Is SAVA Stock Trending Today?
Cassava Sciences (NASDAQ: SAVA ) stock is a hot topic among traders on Tuesday alongside a few important pieces of news that investors need to know about this morning. First off, traders will note that SAVA is a trending stock today.
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
A struggling biotech stock is on the move today on news of a trial extension. Indeed, Cassava Sciences (NASDAQ: SAVA ) has announced that it will be extending trials of simufilam — its lead Alzheimer's disease treatment candidate — by up to 36 months.
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
Cassava Sciences (NASDAQ: SAVA ) stock is up on Monday after the company provided investors with an update for its Phase 3 trial for its Alzheimer's disease treatment. According to a news release from Cassava Sciences, the data from its first Phase 3 clinical trial will come out by December 2024.
Why Cassava Sciences Stock Is Skyrocketing Today
New Cassava executive chairman Rick Barry wrote an open letter to stakeholders. Barry acknowledged skepticism but stressed the potential for its Alzheimer's disease candidate simufilam.
